News

Fundamental research supported by supercomputers could help lead to new strategies and better technology that combats infectious and genetic diseases.

A Phase 2 clinical trial shows that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis Type 1 (NF1).

A new study reports that a subtle modification made to an FDA-approved form of botulinum toxin enhances binding to nerve cells and increases the drug's potency and safety.

MIT biological engineers have created a multitissue model that lets them study the relationships between different organs and the immune system, on a specialized microfluidic platform seeded with human cells.

Synairgen has received expedited approvals from the Medicines and Healthcare products Regulatory Agency and Health Research Authority to conduct a trial of SNG001 in COVID-19 patients to potentially help with the global outbreak of the virus.

Researchers have created a new type of protein reagent for identifying biological sugar structures, which may block the spread of an illness in the body if used for blocking the sugar structures of a cell or a virus.

Chemists have discovered the structure of an unusual bacterial enzyme that can break down an amino acid found in collagen, which could provide a target in treating C. difficile infections.

A team has figured out the details of interleukin-2 (IL-2)’s complex interactions with receptor molecules on immune cells, providing a blueprint for the development of more targeted therapies for treating cancer and autoimmune diseases.

Researchers have developed a new vascular supportive composite bioink using marine algae (alginate) and egg while (albumen), which could be used to 3D print a vascular supportive organ structure.

A drug candidate has been found in preclinical studies to stop tumor growth entirely, delivering more cancer-busting power than many commonly used chemotherapy drugs and with fewer side effects.